Home » Newsletters » BioWorld Science

BioWorld Science

April 15, 2005

View Archived Issues

Close proximity of dopaminergic and serotonergic neurons might explain delayed effects of SSRIs

Antidiabetic effects of cytogenin in streptozotocin-induced diabetes in mice

A novel Stat3 inhibitor as a treatment for breast cancer

Pregabalin provides fast pain relief in postherpetic neuralgia

Promising results obtained with a novel formulation of dronabinol in healthy volunteers

Japanese approval for Vfend

Delay to sBLA filing for Erbitux

Enrollment under way in SYNTAX trial comparing stents to cardiac surgery

Enrollment begins in ENDEAVOR IV study

Osel initiates two Lactin-V phase II studies

Memory extends timeline for safety and tolerability study of MEM-1003

Provectus prepares to study Xantryl in psoriasis and eczema

Series A financing to support Janus pipeline progression

OMS-103HP enters phase III

7TM Pharma and P&G sign research agreement

Enrollment completed in TRIUMPH study of eculizumab for PNH

Phase I/II trial begins for SonoLysis in PAOD

Seattle Genetics inlicenses anti-CD33 antibody program from PDL

Schering-Plough to begin preclinical development of collaborative compound

Vectura and Arakis sign development deal with Novartis for AD-237 for COPD

Alnylam and Benitec sign license agreement in RNAi

Development of a stable and effective vaginal anti-HIV microbicide

New family of non-nucleoside HCMV and VZV inhibitors

NGP-1-01, a promising lead for novel neuroprotective agents

5-HT2C agonists evaluated as therapeutics for urinary disorders

Pieris and Syngenta to develop Anticalins

Recent patents disclose new therapeutic agents for diabetes

Novel agents claimed for transplant rejection and immunological disorders

Japanese approval for Follistim

Raloxifene lowers the risk of cognitive impairment in postmenopausal women

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...